Aligos Therapeutics, Inc. (ALGS) Stock Forecast
ALGS analyst forecast
as of October 18, 2026- Analyst consensus
- Strong buy 4.88 / 5 from 8 analysts
- Price target
- $52.38 average of analyst targets
- Upside to target
- +977.7% from the latest close
- Next earnings
- November 5, 2026 EPS estimate $-2.43
- 52-week range
- $4.08 – $13.29
ALGS analyst ratings
8 analystsNumber of analysts at each rating.
ALGS price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
ALGS earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$2.53 | −$3.04 | −$2.06 | −$3.04 | +16.8% | 6 |
| Current fiscal year (2026) | −$6.52 | −$8.03 | −$4.44 | −$2.45 | −166.1% | 6 |
| Next fiscal year (2027) | −$5.25 | −$7.18 | −$2.78 | −$6.52 | +19.5% | 7 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
ALGS revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $5.5M | $0 | $26.0M | +648.0% | 7 |
| Current fiscal year (2026) | $36.0M | $30.6M | $57.6M | +1,546.5% | 8 |
| Next fiscal year (2027) | $4.7M | $0 | $21.0M | −87.1% | 7 |
ALGS EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
ALGS revenue: reported and forecast
ALGS EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$2.38 | −$2.19 | −$2.15 | −$2.47 | −$2.53 | +6.4% | 2 up · 2 down |
| Current fiscal year (2026) | −$8.07 | −$7.19 | −$7.12 | −$6.34 | −$6.52 | −19.2% | 3 up · 2 down |
| Next fiscal year (2027) | −$4.17 | −$4.14 | −$4.29 | −$5.18 | −$5.25 | +25.7% | 1 up · 4 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
ALGS earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; ALGS beat in 8 of 12.
What analysts expect from ALGS
8 analysts cover Aligos Therapeutics; their consensus rating is strong buy (4.88 on a 1–5 scale, where 5 is a strong buy). The average price target is $52.38, 977.7% above the latest close of $4.86. Analysts expect earnings of −$6.52 per share for 2026, −166.1% from a year earlier. For 2027 the average estimate is −$5.25 per share on revenue of $4.7 million. Aligos Therapeutics beat the EPS estimate in 8 of the last 12 quarters.
Related: ALGS income statement, ALGS key metrics, ALGS chart. See the ALGS stock overview for the latest quote and news.
ALGS forecast FAQ
What is Aligos Therapeutics's price target?
The average analyst price target for Aligos Therapeutics is $52.38, 977.7% above the latest close of $4.86.
Is Aligos Therapeutics a buy, hold or sell?
Of 8 analysts covering Aligos Therapeutics, 7 rate it a strong buy, 1 a buy, 0 a hold, 0 a sell and 0 a strong sell, a consensus of strong buy. Ratings are opinions, not a recommendation from Quotelinks.
What is Aligos Therapeutics's EPS forecast?
Analysts forecast −$6.52 per share for 2026 (range −$8.03 to −$4.44); for 2027 the estimate is −$5.25.
What is Aligos Therapeutics's revenue forecast?
The average revenue estimate for 2026 is $36.0 million, growth of 1,546.5%; for 2027 it is $4.7 million.
When does Aligos Therapeutics report earnings?
Aligos Therapeutics is expected to report results for the quarter ending September 30, 2026 on November 5, 2026 before the market opens; the EPS estimate is $-2.43.
Does Aligos Therapeutics usually beat earnings estimates?
Aligos Therapeutics reported EPS at or above the analyst estimate in 8 of the last 12 quarters.